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Abstract
Hemorrhagic shock (HS) and trauma is currently the leading cause of death in young adults worldwide. Morbidity and
mortality after HS and trauma is often the result of multi-organ failure such as acute lung injury (ALI) and acute respiratory
distress syndrome (ARDS), conditions with few therapeutic options. Bone marrow derived mesenchymal stem cells (MSCs)
are a multipotent stem cell population that has shown therapeutic promise in numerous pre-clinical and clinical models of
disease. In this paper, in vitro studies with pulmonary endothelial cells (PECs) reveal that conditioned media (CM) from MSCs
and MSC-PEC co-cultures inhibits PEC permeability by preserving adherens junctions (VE-cadherin and b-catenin). Leukocyte
adhesion and adhesion molecule expression (VCAM-1 and ICAM-1) are inhibited in PECs treated with CM from MSC-PEC co-
cultures. Further support for the modulatory effects of MSCs on pulmonary endothelial function and inflammation is
demonstrated in our in vivo studies on HS in the rat. In a rat ‘‘fixed volume’’ model of mild HS, we show that MSCs
administered IV potently inhibit systemic levels of inflammatory cytokines and chemokines in the serum of treated animals.
In vivo MSCs also inhibit pulmonary endothelial permeability and lung edema with concurrent preservation of the vascular
endothelial barrier proteins: VE-cadherin, Claudin-1, and Occludin-1. Leukocyte infiltrates (CD68 and MPO positive cells) are
also decreased in lungs with MSC treatment. Taken together, these data suggest that MSCs, acting directly and through
soluble factors, are potent stabilizers of the vascular endothelium and inflammation. These data are the first to demonstrate
the therapeutic potential of MSCs in HS and have implications for the potential use of MSCs as a cellular therapy in HS-
induced lung injury.
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Introduction
Traumatic injury is currently one of the leading causes of death
worldwide. One of the hallmarks of hemorrhagic shock (HS), a
condition resulting from rapid blood loss after traumatic injury, is
the onset of a systemic response that results in endothelial injury,
inflammation, aberrant coagulation, tissue edema and end organ
injury [1]. HS is associated with a high incidence of acute lung
injury (ALI) and acute respiratory distress syndrome (ARDS) (14–
20% of ICU patients) that results in significant morbidity and
mortality [2–7]. There are currently few treatments beyond
supportive therapy to treat lung edema and injury. Over the past
ten years, the therapeutic potential of the multipotent bone
marrow derived stem cell population known as mesenchymal stem
cells (MSCs) have been investigated in multiple disease states
including sepsis [8], acute renal failure [9], graft vs. host disease
[10], ALI [11], and myocardial infarction [12]. MSCs have
multiple characteristics that make them attractive candidates for
clinical translation: 1) They are relatively easy to isolate, 2) They
grow rapidly in culture, and 3) They are able to home to sites of
active tissue injury where they are thought to modulate
inflammation and vascular function [13]. There are currently
154 clinical trials registered with Clinicaltrials.gov investigating the
use of adult MSCs in a number of conditions; however, there are
no clinical trials investigating the use of MSCs in HS, ALI or
ARDS despite the significant pre-clinical data to support their use
and therapeutic benefits. In our past work, we have shown that
intravenously (IV) administered MSCs have potent stabilizing
effects on the vascular endothelium in injury [14] and are capable
of inhibiting blood brain barrier (BBB) permeability after
traumatic brain injury (TBI) via modulation of the adherens
junctions (AJs) proteins: VE-cadherin and b-catenin. In endothe-
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25171lial cells (ECs) these AJ proteins form molecular ‘‘zippers’’
between neighboring ECs, hence regulating paracellular perme-
ability and tissue edema [15]. In addition, our past work has
demonstrated that the influence of MSCs on endothelial per-
meability and barrier function is likely mediated by a secreted
factor(s) that is released as a result of MSC-endothelial cell
interactions. Based upon our past work and that of others
showing that MSCs have potent anti-inflammatory effects in
multiple disease states [13] we hypothesized that MSCs would
have similar stabilizing effects in the lungs exposed to HS. To
address our hypothesis we chose to study pulmonary endothelial
cell-MSC interactions in vitro and the effects of MSCs in vivo in a
rat model of HS and resuscitation.
Methods
Ethics Statement
All experiments involving the use of animals were in compliance
with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the University of Texas
Health Science Center at Houston’s Institutional Animal Care and
Use Committee, #HSC-AWC-10-073.
Primary cells and cell lines
First passage human MSCs and PECs were purchased from
Lonza (Walkersville, MD). MSCs were cultured in MSC growth
media (MSC-GM, Lonza); PECs were maintained in EGM-2MV
media. MSCs were used at passage 3–7 for all experiments. U937s
were obtained from ATCC (Bethesda, MD) and passaged in
RPMI with 10% fetal bovine serum. All cell lines were maintained
at 37uC and 5% CO2.
Flow cytometry
MSCs were characterized by flow cytometry as described
previously [16]. PECs were treated with CM from MSCs,
PEC+MSCs, and PECs alone. Cells were stimulated with TNFa,
50 ng/ml for four hours. After treatment, cells were harvested and
stained with antibodies to VCAM-1 (Becton Dickinson, Franklin
Lakes, NJ), ICAM-1 (Becton Dickinson), E-Selectin (Becton
Dickinson), and P-Selectin (Becton Dickinson). Cells were stained
with secondary antibodies and ran on a flow cytometer (BD
FacsCalibur, BD Biosciences, San Jose, CA).
Flow Cytometry of Adhesion Marker Expression on PECs
Conditioned media was made in three groups: (1) PECs alone,
(2) MSCs alone, (3) PECs/MSCs co-culture. EGM-2 (Lonza) was
added to wells as culture medium. After 48 hours of culture, the
media was removed and stored at 280uC. PECs grown to
confluence on 6 well plates and growth media was replaced with
the conditioned media in the above groups. The experiment was
performed in replicates of four. After 12 hour incubation, TNFa
(50 ng/mL) was added to the wells and incubated for 4 hours. The
cells were then collected and stained with fluorophore conjugated
antibodies to I-CAM, V-CAM, E-selectin, and P-selectin (BD
Biosciences). The cells were then analyzed on the BD LSR II (BD
Biosciences) flow cytometer.
Conditioned media (CM)
PECs were co-cultured in contact with MSCs. 5610
5 cells were
seeded on a 4.67 cm
2 surface area. The ratio of MSCs to PECs
was 0.2 determined by previously reported experiments [14,16].
CM was harvested from co-cultures after 24 hours. See schematic
in Figure 1.
Endothelial cell permeability
Collagen coated 0.4 mm pore size inserts were obtained from
BD Biosciences. PECs were seeded at 40,000 cells per insert well in
a total volume of 500 ml of media and cultured for 8 hours to allow
for cell attachment and adhesion. PEC monolayer permeability
was tested 8 hours later by adding 10 ml of 10 mg/ml 40 kD
FITC-Dextran (Sigma-Aldrich, St. Louis, MO) to the upper
chamber of each well. Monolayers were treated with 10 ng/ml
VEGF-A165 from R&D (Minneapolis, MN), one hour prior to
addition of FITC-Dextran-40 kD. Measurements were deter-
mined with a fluorimeter using excitation and emission wave-
lengths of 485 nm and 530 nm, respectively, from samples
obtained 30 minutes after addition of FITC-Dextran. Data
represent the mean 6 standard error of the mean (SEM) from
three independent experiments. For experiments in which the
effects of CM from MSCs or MSC/PEC co-cultures were studied,
the media from PEC monolayer co-cultures that had been plated
on collagen coated inserts and allowed to adhere was replaced with
undiluted CM and maintained in culture for four hours prior to
addition of FITC-Dextran. Data represent the mean 6 SEM from
three independent experiments.
In vitro VE-cadherin/b-catenin staining (PECs)
Passage 3 PECs were seeded into 8-well glass chambered slides
and grown for 48 hours at 37uC. The cells were then treated with
basal growth media or CM from PEC-MSC co-cultures, PECs
alone, or MSCs alone for 60 minutes at 37uC. To induce
permeability, recombinant human VEGF-A (R&D Systems #293-
VE-010, Minneapolis, MN) was added at 50 ng/mL and
incubated for 30 minutes at 37uC. The cells were then fixed in
2% formaldehyde and blocked in TBST+2.5% normal goat serum
for 60 minutes at room temperature. A rabbit a-VE-cadherin
antibody (1:400 dilution, Cell Signaling #2500 Beverly, MA) and
a mouse a-b-catenin antibody (1:200 dilution, Cell Signaling
#2677) were applied overnight at 4uC and detected using an
Alexa 488 a-rabbit antibody (1:500 dilution, Molecular Probes
#A-11034, Invitrogen, Carlsbad, CA) and an Alexa 568 a-mouse
antibody (1:500 dilution, Invitrogen Molecular Probes #A-11031,
Invitrogen). The next day the slides were mounted using ProLong
Gold anti-fade reagent with DAPI (Molecular Probes P-36931,
Invitrogen) to obtain nuclear staining. Images of the cells were
taken at 406 on a Nikon A1R confocal microscope (Nikon
Instruments, Inc, Melville, NY).
Leukocyte binding assay
PECs were grown to confluence on 96 well plates. 1610‘4 cells/
well were seeded and incubated at 37uC for 2 days or until
confluent. Adhesion molecule expression was stimulated by the
addition of TNFa (50 ng/ml). Cells were treated with CM for
1.5 hours. CM was generated from co-cultured cells and cells
grown alone in PEC growth media. U937 cells were labeled with
Calcein-AM (Invitrogen), added to wells and allowed to adhere for
one hour. Non-adherent cells were gently washed away in
phosphate buffered saline (PBS) and labeled cells that remained
were quantified by fluorescent reading on the Synergy 2
Mircoplate Reader (Biotek, Winooski, VT) at 490 nm wavelength
excitation and 520 nm emission.
Statistical analysis
Data in all graphs is shown as mean 6 SEM. One-way
ANOVA was used for statistical analysis of dose response
permeability studies, adhesion markers and in vivo quantitation of
cytokines and inflammatory infiltrates.
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25171Figure 1. Conditioned media (CM) inhibits permeability and restores adherens junctions (AJs). Figure 1A, CM from MSCs and MSC-PEC
co-cultures inhibits PEC permeability in vitro. A schematic depicting how CM is prepared is shown. MSCs and PECs are cultured separately and
together in co-culture. CM is collected 24 hours later and used in a transwell assay of PEC permeability to 40 kD FITC-Dextran. Figure 1A shows that
CM from both MSCs and MSC-PEC co-cultures inhibits permeability induced by VEGF-A (10 ng/ml). (*) signs indicate significance p,0.05 between
MSC and VEGF and MSC-PEC and VEGF groups. Figures 1B–E, CM from MSCs and MSC-PEC co-cultures restore AJs. PECs were cultured overnight.
After 24 hours, breakdown of AJs (b-catenin and VE-Cadherin) is induced by treatment with VEGF-A (10 ng/ml). Cells were subsequently treated with
CM. Figures 1B–E show that MSC and MSC-PEC CM restored AJ breakdown as determined by confocal microscopy imaging of cultures stained with
antibodies to VE-Cadherin (red) and b-Catenin (green).
doi:10.1371/journal.pone.0025171.g001
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Surgical Preparation: Under isoflurane anesthesia, male Sprague-
Dawley rats (Harlan Laboratories, Indianapolis, IN) were
instrumented by placement of 23 g sterile polyurethane tubing
(Access Technologies, Skokie, IL.) into the femoral artery and
vein. The catheters were subcutaneously tunneled and exited the
dorsal neck. After a 3-day recovery period, the arterial catheter
was connected to a physiological pressure transducer (MLT844,
distributed by AD Instruments, Colorado Springs, CO). Pressures
and heart rates were recorded by a PowerLab 4/30 (AD
Instruments). Rats were randomly assigned to one of four groups.
Group I: Sham. Animals received no injury or treatment. Group
II: HS. Animals received hemorrhage alone. Group III:
HS+resuscitation with Lactated Ringer’s Solution (LR). Animals
received hemorrhage and were then treated with LR (36 shed
blood volume). Group IV: LR+MSC. Animals experienced
hemorrhage, were resuscitated with LR as Group III and also
2610
6 MSCs were administered with LR at 1 and 24 hours, re-
suspended in 100 ml of PBS. Blood samples were taken at 2 hours
post hemorrhage and pressures recorded at baseline, end of
hemorrhage, 1, 2, and 96 hours after hemorrhage. Hemorrhage
was achieved by withdrawing 2 ml/100 g body weight of blood
from the venous or arterial catheter over 10 minutes. This yielded
a 30% blood loss. This procedure was the same for all animals
receiving hemorrhage. Resuscitation was administered at one hour
post hemorrhage. LR was administered at a volume of 3 times the
shed blood volume over 30 minutes. After 96 hours, the rats were
euthanized under isoflurane anesthesia.
Tissue harvesting and sectioning protocol for lung tissue
The lungs were harvested, and used for measurements of wet-to-
dry ratios, molecular biology studies (left side, one lobe) histopa-
thology, and immunohistochemistry (right side, four lobes). Ninety-
six hours after the protocol was started, animals were euthanized
under intubated anesthesia (5% isoflurane through a 16620G
Terumo Surflo I.V catheter). The chest was opened and a
hemostatic clamp was placed on the left main bronchus and
2.5 ml of a solution of 0.5 M sucrose and OCT (Tissue Tek
embedding medium for frozen tissue, Sakura Fineteck USA Inc.,
Torrance, CA) were mixed in equal volume and injected through
theendotrachealtube,tofilltherightlobe.Therightmainbronchus
was clamped, cut over the clamp to secure the embedding media
inside the lobes and tied with 4-O silk. The tissue was immediately
dropped in HistoPrep disposable base molds (Fisher Scientific,
Pittsburg, PA) filled with OCT, wrapped in labeled foil and snap
frozen in liquid nitrogen. This side of the lung was stored at 280uC
and is cryosectioned later for immunohistochemistry staining.
Another piece of lung was fixed in formalin for paraffin fixation
and histopathological analysis. The tissue was moved from the
280uC freezer to the cryostat (Shandon Cryotome SME, Thermo
Fisher Scientific, Waltham, MA). Sections (6 mm) were cut at a
working temperature of 217uC, and mounted to microscope slides
(VWR Vista Vision
TM HistoBondH slides, VWR International,
Radnor, PA). The slides were kept at 280uC until stained.
Immunohistochemistry
Lung sections (6 mm) were cut on a cryostat, mounted on slides,
post-fixed for 20 minutes with 220uC methanol, and rehydrated
in PBS. Sections were incubated in primary antibodies (1.0 mg/ml
in PBS containing 2.5% goat serum and 0.25% Triton X-100) for
48 hours at 4uC, washed in PBS, and then incubated with Alexa
Fluor-conjugated species-specific secondary antibodies for 3 hours
at room temperature. Sections were cover slipped with Fluor-
mount-G (Fisher Scientific), and imaged using an upright
Olympus BX-51 microscope (Bio-Rad Laboratories, Hercules,
CA) attached to a MagnaFire digital camera (Optronics, Goleta,
CA). Bisbenzamide H was added in the final TBS wash sequence
to obtain nuclear staining. Antibodies used: monoclonal to a-
myeloperoxidase antibody (MPO) (Abcam, Cambridge, MA),
CD68 antibody (Abcam), VE-cadherin (Cell Signaling), Occludin-
1 (Invitrogen), Claudin-1 (Invitrogen) and Human mitochondrial
antibody (Millipore, Concord, MA).
Lung wet-to-dry ratios
The clamp was removed from the left bronchus, and the left
lung was harvested. One piece of this lobe was taken, moved to a
small microcentrifuge tube, snap frozen in liquid nitrogen and
stored at 280uC for molecular biology studies (measurement of
cytokines in tissue). The other piece was placed on a labeled plastic
dish. The dish containing the lung was weighed immediately after
harvesting (day 0 weight), and then stored in a 50uC oven to dry
for 72 hours and reweighed (day 3 weight) to calculate the wet-to-
dry ratio. The ratios between the day 0 and day 3 weights are the
wet-dry/dry ratios and are considered a measurement of lung
edema.
Cytokine and chemokines by Bioplex (tissue and serum)
Cytokines were measured in the tissue at four days and in the
serum at two hours. Two hours was picked as the main time point
to determine inflammatory changes since previous studies with this
model had shown that the maximum changes in inflammatory
cytokines occur between 1–4 hours after HS [17–19]. The Bio-
Plex cytokine assay system (Bio-Rad Laboratories) and concen-
trations of IL-1a, IL-1b, IL-6, IL-10, MIP-1a, MCP-1 and TNFa
were simultaneously evaluated using a commercially available
multiplex bead-based immunoassay (Rat 9-Plex, Bio-Rad Labo-
ratories). The assay was performed per the manufacturer’s
instructions and the details have been previously published by
our group and others [20]. High standard curves (low RP1 target
value) for each soluble cytokine were used, ranging from 2 to
32,000 pg/ml. A minimum of 100 beads per cytokine region were
evaluated and recorded. Values with a coefficient of variation
beyond 10% were not included in the final data analysis. All
samples were run in duplicate.
Results
Conditioned media from MSCs inhibits pulmonary
endothelial cell permeability in vitro
In our past work with human umbilical vein endothelial cells
(HUVECS), we have shown HUVECs in contact with MSCs
produce a soluble factor(s) that inhibits paracellular permeability
and may be responsible for the enhanced barrier integrity in
MSC/HUVEC co-cultures [14]. To gain further insight into the
mechanism by which MSCs could potentially modulate PEC
permeability, we investigated whether MSCs could inhibit
paracellular permeability in PECs. We tested the CM from cells
grown in two different formats (MSCs alone and PEC+MSCs) for
their ability to reduce paracellular permeability induced by
VEGF-A. In each format, the total number of cells seeded in
the culture was held constant at 2610
5 cells per well. For the co-
cultured conditions, MSCs were added to give a final MSC to
PEC ratio of 0.2; we have previously used this ratio to demonstrate
effects on endothelial function [14,16]. Conditioned media was
harvested 24 hours after seeding and tested for their effect on
permeability (Figure 1A). Permeability to 40 kD FITC-Dextran
for each culture condition was assessed and normalized to the
permeability values obtained using CM from PECs alone.
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induced by VEGF-A and is inhibited by CM from MSC as well as
MSC-PEC. This finding differs from our previous results with
HUVECs, where the effects on permeability were only noted in
the CM from HUVEC-MSC co-cultures, indicating that the
effects may be dependent on the endothelial cell type since the
endothelium is highly heterogeneous and varies greatly between
the organ of origin [21].
MSCs increase VE-cadherin/b-catenin interaction at the
cell surface of PECs
As mentioned previously, AJs (VE-cadherin and b-catenin) are
critical regulators of vascular integrity and permeability [22,23].
To determine if b-catenin is involved in the decrease in barrier
permeability we observed (Figure 1B), we looked at the effects of
the MSCs on b-catenin and VE-cadherin localization in PECs
treated with CM from MSCs and MSCs+PECs as described
above. Figures 1C–E reveal that CM from MSCs and MSC-PEC
co-cultures restore AJs (b-catenin and VE-cadherin) staining at the
surface of PECs that have been treated with VEGF-A. PECs
treated with CM from MSCs and MSC-PEC co-cultures
demonstrate enhanced VE-cadherin and b-catenin immunoreac-
tivity at the membrane and an enhanced propensity to grow in
clusters. Furthermore our findings with CM suggest, as we have
found in past work, that a secreted factor(s) from MSCs is
responsible for improving the barrier integrity of PECs. Interest-
ingly, in these studies with PECs, we find that CM from MSCs
alone has potent effects on AJs and permeability.
MSCs inhibit leukocyte adhesion to PECs
Multiple factors are responsible for the compromise of the
endothelial barrier in HS-induced lung injury. In addition to
factors such as hypoxia and thrombin, inflammatory changes
caused by cytokine and chemokine release, leukocyte adhesion,
diapedesis and infiltration into the lungs have all been shown to
contribute to the clinical severity and outcome in ALI/ARDS [4].
We sought to determine if MSCs modulate leukocyte binding to
PECs stimulated with the inflammatory cytokine TNFa. In these
studies, PECs were treated with CM from MSCs and MSC-PEC
co-cultures. To stimulate inflammatory cell (U937) binding, PECs
were treated with TNFa (50 ng/ml) which increased U937 cell
binding as depicted in Figure 2A. U937 cells are a monocytoid line
that we have previously used to study leukocyte-endothelial
adhesion [24]. Binding of calcein-labeled cells to treated PECs
was quantified by relative fluorimetric. Binding studies reveal that
pre-treatment of the PECs with CM media from MSC or MSC-
PEC co-cultures inhibit U937 binding to the PECs (Figure 2B).
Flow cytometric analysis of the treated PECs reveals that CM from
MSC+PECs co-culture, but not MSC CM, inhibit TNFa
mediated increases in ICAM-1, and VCAM-1, suggesting a
contact-mediated effect. E-selectin and P-selectin were unchanged
by either treatment, suggesting that the effects of the MSC-PEC
CM is on firm adhesion of leukocytes and not tethering and rolling
processes typically regulated by the selectins (Figures 2C–2F).
Taken together, our findings suggest that the therapeutic effects of
MSCs are not solely due to enhancement of barrier integrity, but
do have direct effects on inflammatory cell binding to the
endothelium. It is of interest to note that we find effects of the
MSC CM media alone on EC permeability, but in the case of
leukocyte binding, the effects are limited to co-cultured MSC-PEC
CM. These findings suggest that the soluble factors mediating
barrier integrity may be different from those mediating inflam-
mation and leukocyte adhesion, indicating a decoupling of these
effects. To determine if our in vitro findings translate into similar
effects in a rat model of HS, we administered MSCs IV after
hemorrhage with specific focus upon the effects on endothelial
integrity and inflammation in the lungs.
IV Administration of MSCs in rats subjected to HS does
not affect mean arterial pressure (MAP) in treated
animals
Using a well characterized rat model of mild, non lethal HS
[14,25], we sought to determine if administration of IV MSCs
after hemorrhage affected MAP. Rats were randomly assigned to
four main groups with anticipated 100% survival in all groups.
Animals underwent hemorrhage with removal of 2 ml/100 g of
blood over 10 minutes. MAP fell to approximately 30 mmHg in
all groups. After a 60 minute period of shock, animals were
resuscitated. Groups were as follows (Figure 3A): Group I: Sham-
animals received no injury or treatment. Group II: HS- animals
received hemorrhage alone. Group III: HS+LR. Animals
underwent hemorrhage and were then resuscitated with LR.
Group IV: LR+MSC- rats were resuscitated with LR as in Group
III plus 2610
6 MSCs were administered with LR at 1 hour post
hemorrhage and a second dose in 100 ml of LR at 24 hours after
hemorrhage. Dosing of MSCs was determined by our past work
and that of others in disease models of vascular stability [16,26].
The logic behind our selection of LR was to mimic the early stages
of resuscitation in trauma patients when MSCs could potentially
be used as an adjunct to resuscitation. The goal would be to
administer MSCs at an early time point to promote vascular
stability and prevent the development of ALI/ARDS or multi-
organ failure (MOF). Human MSCs were obtained commercially
(see methods) from four young, healthy donors for use in all
experiments. Our choice to use human MSCs in the rat was
prompted by our past work showing no acute evidence of rejection
and previous findings that human MSCs may act differently then
rat MSCs [27,28]. Prior to using these cells for in vitro and in vivo
experiments, fluorescence activated cell sorting (FACS) analysis
was performed to examine the expression of characteristic MSC
cell surface markers. Cells were confirmed to display characteristic
MSC cell surface markers [16], including high levels of CD44 and
CD105, and an absence of CD31 expression (data not shown).
Figures 3B and 3C show that there are no significant changes in
hemorrhage volume and weight respectively between animals in
all three groups subjected to hemorrhage. Figure 3D demonstrates
no differences in MAP in all three groups. The MAP dropped soon
after hemorrhage and was essentially restored in all groups by one
hour post hemorrhage.
IV administration of MSCs in rats subjected to HS inhibits
edema and inflammatory cell infiltrates in the lungs of
treated animals
To determine if lung edema and injury were generated by the
hemorrhagic insult, lungs were taken for wet-to-dry analysis. Wet-
to-dry-analysis (Figure 4A) revealed that mild edema is present in
Group II (HS alone). Resuscitation with LR (Group III) did not
significantly increase the amount of lung edema above HS (Group
II), but MSCs (Group IV) did indeed significantly decrease the
amount of edema compared to LR (Group III) and HS (Group II),
thus this data suggests that IV MSCs may have modulator effects
upon vascular stability in the lungs after HS. Histopathological
(H&E) analysis (Figure 4B) of tissue sections from rat lungs indicate
that animals treated with MSCs show attenuated injury. Further
histopathological analysis reveals that MSC treated animals have
decreased numbers of CD68 positive cells, a general surface
marker of leukocytes and lymphocytes, in the lungs compared to
Pulmonary Effects of MSCs in Hemorrhagic Shock
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25171Figure 2. CM inhibits adhesion of U937s and adhesion molecule expression in PECs. Figures 2A and 2B, CM from MSC and MSC+PEC co-
cultures inhibits adhesion of U937 to PECs. Calcein labeled U937 cells were allowed to adhere to PECs that had been pre-treated with CM from PEC
and MSC-PEC co-cultures. Cultures were stimulated with TNFa and U937s were added to the wells. After gentle washing, bound cells were
quantitatively and qualitatively assessed. Figure 2A shows decreased binding of U937 (green dots) in CM treated cultures. Figure 2B shows
quantitative significant decreases in CM treated cultures as indicated by (*), which signifies p,0.05 between control (TNFa treated cells) and MSC CM
and control and CM-CO (MSC-PEC CM). ‘‘Unstim’’ represents the group not treated with TNFa. Eight wells were included in each group (n=8).
Figures 2C–F, CM from MSC+PEC co-cultures inhibits PECs expression of adhesion molecules VCAM-1 and ICAM-1. Conditioned media was made in
three groups: (1) PECs alone, (2) MSCs alone, (3) PECs/MSCs co-culture. EGM-2 (Lonza) was added to wells as culture medium. After 48 hours of
culture the media was removed and stored at 280uC. PECs grown to confluence on 6 well plates and growth media was replaced with the
conditioned media in the above groups. The experiment was performed in replicates of four. After 12 hour incubation, TNFa (50 ng/mL) was added
to the wells and incubated for 4 hours. The cells were then collected and stained with fluorophore conjugated antibodies to I-CAM, V-CAM, E-
selectin, and P-selectin. The cells treated with PEC/MSC conditioned media demonstrated decreased I-CAM and V-CAM expression compared to both
those treated with PEC or MSC conditioned media(p,0.01, ANOVA). This difference was not seen in E-selectin or P-selectin.
doi:10.1371/journal.pone.0025171.g002
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qualitative differences in CD68 staining between Group IV and
Group II and III. Figure 4C quantitatively demonstrates decreased
numbers of CD68 positive cells in MSC-treated lungs with numbers
similar to sham animals (Group I). Further evidence of a decrease in
neutrophilic infiltration in MSC treated lungs is evident from
immunofluorescence staining for myeloperoxidase (MPO) positive
cells (Figure 4E and 4F). MPO staining is significantly decreased in
Group IV (MSCs) compared to Group II (HS) and Group III (LR).
Once again, numbers of MPO positive cells in MSC-treated
animals are close to those found in Group I (sham), consistent with
inhibition of pulmonary inflammation.
IV administration of MSCs in rats subjected to HS inhibits
TNFa, MCP-1, MIP-1a and augments IL-10
In light of our findings with changes in inflammatory cells in the
lungs, we sought to determine if inflammatory cytokines and
chemokines changed in animals treated with MSCs. Serum
collected at two hours post-hemorrhage was subjected to multiplex
bead-based cytokine analysis as described in the methods. Two
hours was picked as the main time point to determine inflammatory
cytokine and chemokine changes since previous studies with this
model had shown that the maximum changes in inflammatory
cytokines occur between 1–4 hours after HS. Serum from animals
subjected to HS revealed significant rises in TNFa, MCP-1, MIP-
1a, and IL-10 (Figures 5A, 5B, 5C, and 5D). Animals treated with
MSCs (Group IV) showed decreases in TNFa, MCP-1 and MIP-1a
compared to HS (Group II) and LR (Group III). Interestingly,
MSC-treated animals demonstrated a significant rise in the anti-
inflammatory cytokine IL-10 (Figure 5D). Tissue levels and serum
levels of these same four cytokines and chemokines were unchanged
in lung tissue that was harvested at 96 hours post-hemorrhage,
indicating resolution of the inflammatory process from this insult by
four days post hemorrhage (data not shown).
MSCs preserve vascular tight junctions and AJs in the
lungs of MSC treated rats
Previously, we have shown that IV MSCs administered after
TBI inhibit BBB permeability through preservation of AJs and
tight junctions in the brain [17]. AJs and tight junctions regulate
vascular integrity and paracellular permeability in vascular
endothelium. VE-cadherin-VE-cadherin homophilic interactions
on endothelial cells are crucial for maintaining normal vascular
integrity and inhibiting permeability [15,29]. These junctions link
the extracellular environment to the intracellular environment by
recruiting and binding b-catenin, which then binds to the actin
cytoskeleton via other intermediate proteins within the cytoplasm
[15]. Since we found a decrease in lung edema with MSCs in our
rodent model of HS, we sought to determine if MSCs preserve or
increase tight junctions in the lungs. To confirm presence and
determine the location of the MSCs in the lungs of treated
animals, we stained lung tissue for human mitochondria using an
antibody that does not cross-react with murine mitochondria (see
methods), thereby allowing us to locate the human MSCs.
Immunoflourescent staining of the lungs reveals that the majority
of the MSCs are located in the perivascular space adjacent to vessel
lumens, with some present in the lung parenchyma as well
(Figure 6A). Figure 6B shows that rats subjected to HS and LR
resuscitation exhibit diminished stainingof AJ proteinVE-cadherin,
which is spared significantly in MSC-treated animals. Morpholog-
ical analysis reveals a slight thickening the AJs (Figure 6B).
Furthermore, similar sparing effects are found for Occludin-1 and
Claudin-1 (Figure 6C) in MSC treated rats. Both markers are tight
junction proteins, indicating that MSCs may work in a similar
fashion in HS as we had found in TBI, to reinforce and enhance
vascular integrity after injury. These molecular changes are
consistent with our in vitro findings demonstrating that MSC CM
inhibits lung endothelial cells, permeability and AJ integrity.
MSCs enhance pericyte/smooth muscle cell presence in
lung capillaries
The endothelial-organ barrier is composed of multiple compo-
nents acting together to maintain barrier integrity. It is
heterogeneous throughout the body and its function and structure
are dependent upon the organ of interest. To maintain the stable
environment required for the effective function, capillaries in the
lung consist of a single layer of endothelial cells interconnected by
tight junction proteins, AJs and pericytes/smooth muscle cells that
reside adjacent to the endothelial cells and result in a continuous
basal lamina [30–32]. Breakdown of the barrier, which occurs in
lung injury, leads to infiltration of blood components, inflamma-
tory cells and fluid into lung alveoli and interstitial space, causing
increased free radical production, inflammation, edema and
compromised gas exchange and lung function. Pericytes, although
decreased in number in the lungs, have been shown to be key
components reinforcing barrier integrity. To study pericyte/
smooth muscle cell and basal lamina structure in the lungs, lung
sections were stained for PDGF Receptor b, a marker for pericytes
and vascular smooth muscle cells (SMC). In small capillaries
(,10 um) few SMCs are present. Qualitative immunoflourescent
staining for PDGFRb in lung microvasculature reveals positive
staining (green) around capillary blood vessels, defined by vWF
staining (red) (Figure 6D). Animals subjected to HS reveal
diminished pericyte/SMC staining in the lungs (Figure 6E), which
is preserved and seemingly enhanced in MSC treated animals
(Figure 6F). LR resuscitation (Figure 6G) also partially restores
pericyte/SMC presence in the lungs. Since MSCs are known to be
PDGFRb positive and work by others has shown them to have
multiple characteristics similar to pericytes [33–37], we co-stained
lung sections for MSCs using the human mitochondrial marker
and PDGFRb. Figure 6H reveals that MSCs do indeed stain
positive for PDGFRb along the vessel lumen, but not at the
perivascular periphery of the vessels, thereby indicating that the
seemingly enhanced presence of pericytes/SMC in MSC treated
animals is not likely due to perivascular MSCs.
Discussion
Our work demonstrates that MSCs can have stabilizing effects
upon the lung vasculature after HS. Overall we demonstrate that
MSCs inhibit EC barrier permeability and preserve pulmonary
endothelial cell integrity by preserving AJs, tight junctions and
Figure 3. In Vivo IV MSCs do not alter mean arterial pressure (MAP) in rat model of hemorrhagic shock and resuscitation. Figure 3A
shows a schematic of the in vivo rat model. Animals were pre-instrumented three days prior to hemorrhage. Hemorrhage of fixed volume at a rate of
2 ml/100 g/10 minutes was performed. One hour later, resuscitation of Lactated Ringer’s (LR) (36shed blood) was administered. MSCs at a dose of
2610
6 were administered with LR at 1 and 24 hours post hemorrhage. Blood was drawn at 0, 2 and 96 hours. Tissues were harvested on day four.
Figures 3B and 3C show that hemorrhage volume and weight of rats is similar in all groups. Figure 3D shows that MAP drops respectively in all
hemorrhaged groups and returns to normal by 2 hours post-hemorrhage. MSC administration does not affect MAP.
doi:10.1371/journal.pone.0025171.g003
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e25171decreasing inflammation. In vitro we find that CM (from MSCs and
MSCs+PECs) inhibits PEC permeability and leukocyte adhesion
respectively. These findings indicate that a soluble factor(s)
produced by MSC administration could potentially be the
mediator of many of the noted beneficial therapeutic effects of
MSCs in disease states characterized by vascular instability and
inflammation. Support for the therapeutic effects of a number of
MSC derived factors has been shown by others investigating their
use in lung injury [38–41]. In our in vivo rat model of mild HS, we
find presence of MSCs in the vasculature of the lungs associated
with decreased lung interstitial edema, preservation of AJs and
decreased inflammatory infiltrates. The anti-inflammatory effect of
Figure 5. TNFa, MIP-1a, and MCP-1 are decreased and anti-inflammatory cytokine IL-10 is increased by MSC treatment. Blood was
drawn at two hours post-hemorrhage and analyzed for serum levels of TNFa, MCP-1, IL-10 and MIP-1a. As shown in Figures 5A–C, bioplex analysis of
serum shows that MCP-1, TNFa, and MIP-1a all significantly increase after HS and HS+LR. This rise is significantly decreased by MSC administration
(* indicates p,0.05 for HS vs. LR+MSC and LR vs. LR+MSC). Figure 5D shows that anti-inflammatory cytokine IL-10 is significantly increased by MSC
(Figure 5D).
doi:10.1371/journal.pone.0025171.g005
Figure 4. MSCs inhibit lung edema and inflammatory cells in HS rats. Figure 4A, MSCs inhibit interstitial lung edema. Wet-to-dry ratios of
lung tissue calculated as described in materials and methods demonstrate that mild edema is produced by HS in rat lungs. (* indicates p,0.05
between LR and LR+MSC). This small increase in edema remains with the administration of LR, but is diminished in animals receiving LR+MSCs,
thereby indicating that MSCs inhibit HS induced lung edema. Figure 4B shows H&E staining of MSC treated lungs suggested decreased edema and
injury. Representative lung sections from the four groups were stained for H&E. Gross histopathological analysis demonstrates decreased edema and
inflammation in MSC treated lungs. HS and HS+LR treated groups show edema and inflammatory infiltrates (see arrows). Figures 4C and 4D show that
inflammatory CD68 positive cells are decreased in MSC treated lungs. Lung sections were stained for CD68, a marker of inflammatory monocytes and
macrophage infiltrates. Five sections were analyzed per animal (n=5) and 8–10 high power fields were counted for fluorescent positive (CD68+) cells.
Figure 4C shows that CD68+ cells are significantly decreased in MSC treated animals (* indicates p,0.05). MSC treated animals were not significantly
different from Shams. Figure 4D shows representative fluorescent images of the CD68+ cells in the lungs. Figures 4E and 4F, Myeloperoxidase positive
cells are decreased in MSC treated lungs. Myeloperoxidase (MPO) staining of MSC treated lungs shows decreased MPO positive cells. Representative
stained sections are shown in Figure 4F.
doi:10.1371/journal.pone.0025171.g004
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tory cytokines and chemokines and an increase in the anti-
inflammatory cytokine, IL-10. IL-10 has been shown by others to
be a key mediator of MSC action in LPS models of lung injury [8].
Interestingly, we also found an increase in the pericyte/smooth
muscle component of the vascular barrier, an effect that could add
to strengthening of the alveolar capillary barrier.
Abnormalities in vascular permeability leading to inflammation,
tissue edema and end-organ dysfunction significantly contribute to
the morbidity and mortality associated with a number of human
disease processes [42]. The endothelial barrier as a target for
therapy is a concept that is slowly becoming recognized as one
with significant potential [43]. Both HS and septic shock are
characterized by abnormal vascular permeability [1,14], which
contributes to the development of multi-organ failure and is the
primary cause of shock-associated ALI and ARDS [2]. Despite the
clear importance of abnormal vascular permeability in a number
of human disease processes, no current therapeutic in use targets
vascular permeability and its consequent adverse results. Taken
together, our findings suggest that MSCs, and possibly systemic
Figure 6. MSCs in the lung vasculature. Figures 6A-C show, IV MSCs localize to the lung vasculature and preserve integrity of AJs and tight
junctions (TJs). Figure 6A, MSCs (see white arrow) were detected around blood vessels in the lungs (BVL=blood vessel lumen) using a human
mitochondrial antibody (green) showing staining in lung tissue from MSC treated rats. (red=VE-Cadherin and DAPI staining nuclei -blue). Figure 6B:
Staining of blood vessels in lungs (BVL=blood vessel lumen) for VE-Cadherin (red) and b-catenin (green) shows that in the LR group, HS and
resuscitation compromise the continuity of the AJs (see white arrow). This continuity is preserved in MSC treated animals. Figure 6C: Similar findings
are found for TJs staining of Occludin-1 (green) and Claudin-1 (red). MSCs preserve compromise of TJs in the lungs (see white arrows). Morphological
changes (thickening) in AJs and TJs are noted in MSC treated lung vessels (long white arrows). Figures 6D–H show MSCs preserve PDGFRb positive
pericytes on lung microvasculature after HS. Sectioned lung tissue was stained for PDGFRb (green) to identify pericytes or smooth muscle (SM) cells
and vWF (red) to identify blood vessels. Figures 6E and 6F shows that HS and LR groups show diminished or compromised PDGFRb staining (small
white arrows), indicating decreased pericyte/SM cell coverage on microvasculature. This is increased above Sham (Figure 6D) in MSC treated animals
(Figure 6G-see large white arrow). Figure 6H shows that MSCs (red) contribute to some, but not all, of the increased PDGFRb (green) staining found in
treated lungs.
doi:10.1371/journal.pone.0025171.g006
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target vascular permeability and inflammation through local and
systemic effects.
The lung is an organ that is highly susceptible to edema and
endothelial permeability after traumatic injury. ALI and ARDS
are common complications with the annual incidence in ICU
patients as high as 20% with coincident mortality ranging from
50–70% [3–7]. Increased vascular permeability has been shown to
persist over the course of ARDS and is related to the clinical score
of injury severity and outcome [3]. The pathophysiology of this
process is still unclear, but a large number of inflammatory
mediators and cells contribute to its development. In the exudative
phase of lung injury, alveolar capillary endothelial cells and type I
pneumocytes are compromised, thereby resulting in a loss of the
barrier that prevents fluid and macromolecule leak. Inflammatory
cells and cytokines lead to continued endothelial injury. The
component that occurs first, endothelial permeability or inflam-
mation, is not clear and is the subject of the current study. Our
findings demonstrate that IV MSCs address both components of
endothelial permeability and inflammation induced by HS. This is
the first study to report the therapeutic benefits of MSCs in HS. It
will be of interest to determine in future studies if MSCs mitigate
outcome in a more severe model of HS.
Currently there are a number of groups investigating novel cell-
based therapies for sepsis-induced ALI/ARDS [40]. MSCs possess
biological properties that make them an ideal cell-based therapeutic
for pathologic edema associated with trauma-related conditions
[44,45]. MSCs can be readily expanded to hundreds of millions of
cells, proliferate for many passages in culture, and are easily
transfected, allowing for easy ex vivo modification with genes of
interest. In lung injury, MSCs have been shown to have potent
effects in pre-clinical models of ALI induced by sepsis,characterized
by lung edema and inflammation [11,46]. In many models, MSCs
were able to modulate the immune system through the release of
anti-inflammatory cytokines, inhibition of inflammatory cytokines
and release of lipid mediators such as prostaglandin E2 [8]. A recent
Figure 7. Soluble factors play a role in the effects of IV MSCs in vivo. Figure 7 shows a working biological model of how MSCs may function
biologically when delivered IV after HS. MSC attach to pulmonary vascular endothelial cells in the lungs where they produce soluble factor(s) that
affect vascular stability in the lungs through modulation of AJs, TJs and checking inflammation. We hypothesize that the soluble factor(s) produced
promote local and systemic vascular stability.
doi:10.1371/journal.pone.0025171.g007
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keratinocyte growth factor (KGF), a factor that restores lung
epithelial and endothelial permeability [40]. Taken together, these
published findings support our current findings that MSCs have
global effects on vascular permeability and stability, likely due to
soluble factors that mediate these effects.
In our future work we will study the effects of MSCs in a more
severe animal model of hemorrhagic shock and trauma. This more
severe model will most likely produce fulminant ALI or ARDS. It
is quite typical that most hemorrhagic shock models do not
produce much lung edema, but rather a modest increase in lung
endothelial permeability with some interstitial edema, as we have
shown. However, there is extensive clinical and pre-clinical data
supporting a direct correlation between lung interstitial edema and
pulmonary function [47]. Taking into account that normally the
distance between the pulmonary microvasculature and the alveoli
forming the alveolar capillary barrier for gas exchange is small (1–
2 microns), it is likely that small perturbations in this limited
interstitial area would impact gas exchange. Future studies will
establish the effects of MSCs on oxygenation and lung compliance.
Based upon the findings of others, we anticipate this will be the
case for a severe model of HS.
Another future direction of this research would be to identify the
soluble factor(s) that can be used as a ‘‘cell-free’’ therapeutic to
recapitulate the beneficial effects of MSCs (Figure 7, working
biological model). There are clear advantages from a translational
standpoint in injured patients; MSCs administered after trauma
may have potent therapeutic effects, but are difficult to harvest
rapidly and administer as an autologous treatment option.
Heterologous transfer is complicated by the potential for rejection
and storage problems. If a soluble factor(s) can recapitulate these
effects, confirmation of its presence and functional properties in
vivo, and ultimately determination of its identity, can result in a
novel ‘‘cell-free’’ treatment option for injured patients. Although
most perceive the effect of MSCs to be due to their presence in the
injured organ, many groups are realizing that secreted factors play
a large role in the noted beneficial effects of stem cells in models of
injury. Future pre-clinical and clinical studies in HS and trauma
will assess these effects.
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